ATE251750T1 - Verwendung von 5,10,15,20-tetrakis(r- carboxyphenyl)porphin zum nachweis und zur behandlung von lungenkrebs - Google Patents

Verwendung von 5,10,15,20-tetrakis(r- carboxyphenyl)porphin zum nachweis und zur behandlung von lungenkrebs

Info

Publication number
ATE251750T1
ATE251750T1 AT91913465T AT91913465T ATE251750T1 AT E251750 T1 ATE251750 T1 AT E251750T1 AT 91913465 T AT91913465 T AT 91913465T AT 91913465 T AT91913465 T AT 91913465T AT E251750 T1 ATE251750 T1 AT E251750T1
Authority
AT
Austria
Prior art keywords
porphine
carboxyphenyl
tetrakis
radiotracer
copper
Prior art date
Application number
AT91913465T
Other languages
English (en)
Inventor
Dean A Cole
David C Moody Iii
L Edward Ellinwood
M Gerard Klein
Original Assignee
Univ California
Sisters Of Charity Of Leavenwo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Sisters Of Charity Of Leavenwo filed Critical Univ California
Application granted granted Critical
Publication of ATE251750T1 publication Critical patent/ATE251750T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0485—Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1206—Administration of radioactive gases, aerosols or breath tests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/968—High energy substrates, e.g. fluorescent, chemiluminescent, radioactive
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/80—Fluorescent dyes, e.g. rhodamine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/805—Optical property

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Optics & Photonics (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Atmospheric Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT91913465T 1990-06-15 1991-06-17 Verwendung von 5,10,15,20-tetrakis(r- carboxyphenyl)porphin zum nachweis und zur behandlung von lungenkrebs ATE251750T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/539,999 US5162231A (en) 1989-10-25 1990-06-15 Method of using 5,10,15,20-tetrakis(carboxyphenyl)porphine for detecting cancers of the lung
PCT/US1991/004132 WO1991019977A1 (en) 1990-06-15 1991-06-17 USING 5,10,15,20-TETRAKIS(r-CARBOXYPHENYL)PORPHINE FOR DETECTING AND TREATING LUNG CANCER

Publications (1)

Publication Number Publication Date
ATE251750T1 true ATE251750T1 (de) 2003-10-15

Family

ID=24153544

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91913465T ATE251750T1 (de) 1990-06-15 1991-06-17 Verwendung von 5,10,15,20-tetrakis(r- carboxyphenyl)porphin zum nachweis und zur behandlung von lungenkrebs

Country Status (15)

Country Link
US (2) US5162231A (de)
EP (1) EP0533845B1 (de)
JP (1) JP3047468B2 (de)
KR (1) KR0171393B1 (de)
AT (1) ATE251750T1 (de)
AU (2) AU8061491A (de)
BR (1) BR9106563A (de)
CA (1) CA2085464C (de)
DE (1) DE69133325T2 (de)
DK (1) DK0533845T3 (de)
FI (1) FI925673A (de)
HU (1) HUT63499A (de)
NO (1) NO924820L (de)
RU (1) RU2114430C1 (de)
WO (2) WO1991019978A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622685A (en) * 1990-05-30 1997-04-22 Deutches Krebsforchunszentrum Stiftung Des Offentlichen Rechts Polyether-substituted porphyrin anti-tumor agents
US5252698A (en) * 1992-10-09 1993-10-12 Sri International Metal ion porphyrin-containing poly(azine)
US5464741A (en) * 1993-10-08 1995-11-07 Henwell, Inc. Palladium (II) octaethylporphine alpha-isothiocyanate as a phosphorescent label for immunoassays
US6490330B1 (en) * 1994-04-12 2002-12-03 The Regents Of The University Of California Production of high specific activity copper -67
US5716958A (en) * 1994-10-27 1998-02-10 Tobishi Pharmaceutical Co., Ltd. Amino acid derivative having anti-CCK activity
US5591422A (en) * 1995-06-02 1997-01-07 Pharmacyclics, Inc. Texaphyrin complexes having improved functionalization
CA2309154C (en) 1997-11-03 2010-02-16 Duke University Substituted porphyrins
US6703050B1 (en) * 1998-09-04 2004-03-09 The Regents Of The University Of Michigan Methods and compositions for the prevention or treatment of cancer
DK1155019T3 (da) 1999-01-25 2006-04-18 Nat Jewish Med & Res Center Substituerede porphyriner og deres terapeutiske anvendelse
US6190877B1 (en) * 1999-12-27 2001-02-20 Edwin L. Adair Method of cancer screening primarily utilizing non-invasive cell collection and fluorescence detection techniques
US6750037B2 (en) * 1999-12-27 2004-06-15 Edwin L. Adair Method of cancer screening primarily utilizing non-invasive cell collection, fluorescence detection techniques, and radio tracing detection techniques
US6984498B2 (en) * 1999-12-27 2006-01-10 Adair Edwin L Method of cancer screening primarily utilizing non-invasive cell collection, fluorescence detection techniques, and radio tracing detection techniques
US6575888B2 (en) * 2000-01-25 2003-06-10 Biosurface Engineering Technologies, Inc. Bioabsorbable brachytherapy device
KR100390771B1 (ko) * 2000-08-31 2003-07-10 한국화학연구원 광역학 치료(ｐｄｔ)용 광민감성 물질로 유용한 포르피린유도체
JP4307070B2 (ja) * 2000-11-17 2009-08-05 バイオモーダ・インコーポレーテツド ５，１０，１５，２０−テトラキス（カルボキシフェニル）ポルフィンを使用する、細胞および組織サンプルにおける前がん症状を検出するための組成物および方法
EP1392328B1 (de) 2001-01-19 2009-08-12 National Jewish Medical and Research Center Medikament zum schutz in der radiotherapie
WO2002098431A1 (en) 2001-06-01 2002-12-12 National Jewish Medical And Research Center Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
US6566517B2 (en) * 2001-06-06 2003-05-20 Brookhaven Science Associates, Llc Metalloporphyrins and their uses as imageable tumor-targeting agents for radiation therapy
EP1487983A4 (de) * 2002-03-01 2007-08-15 Sloan Kettering Inst Cancer Verhinderung des wiederauftretens und der metastasierung von krebs
AU2003237500A1 (en) 2002-06-07 2003-12-22 Duke University Substituted porphyrins
DE60307545T2 (de) * 2002-06-21 2007-10-04 Adair, Edwin L., Castle Pines Village Anwendung von Metalloporphyrinen zur Behandlung von Arteriosklerose
US7888389B2 (en) 2002-07-23 2011-02-15 The Regents Of The University Of Michigan Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
US20070149496A1 (en) * 2003-10-31 2007-06-28 Jack Tuszynski Water-soluble compound
US6995260B2 (en) * 2004-05-20 2006-02-07 Brookhaven Science Associates, Llc Carboranylporphyrins and uses thereof
US6989443B2 (en) * 2004-06-28 2006-01-24 Brookhaven Science Associates, Llc Carboranylporphyrins and uses thereof
US20060094682A1 (en) * 2004-10-29 2006-05-04 Odyssey Thera, Inc. Kinase inhibitors for the treatment of diabetes and obesity
US8160675B2 (en) * 2006-05-17 2012-04-17 Koninklijke Philips Electronics N.V. Retrospective sorting of 4D CT into breathing phases based on geometric analysis of imaging fiducials
US9957293B2 (en) * 2006-08-23 2018-05-01 Yeda Research And Development Company Ltd. Conjugates of RGD peptides and porphyrin or (bacterio)chlorophyll photosynthesizers and their uses
US8287839B2 (en) * 2006-12-04 2012-10-16 Brookhaven Science Associates, Llc Carboranylporphyrins and uses thereof
US8444953B2 (en) * 2007-03-22 2013-05-21 Brookhaven Science Associates, Llc Symmetric and asymmetric halogen-containing metallocarboranylporphyrins and uses thereof
US20080279781A1 (en) * 2007-05-10 2008-11-13 Brookhaven Science Associates, Llc Glycosylated Carboranylporphyrins and Uses Thereof
ES2600469T3 (es) 2008-05-23 2017-02-09 National Jewish Health Un compuesto para su uso en el tratamiento de lesiones asociadas con la exposición al gas fosgeno o al gas de cloro
CN103168234B (zh) * 2009-07-17 2015-11-25 保爱菲技术公司 用于分析被5，10，15，20四(4-羧基苯基)卟吩(tcpp)标记的样品的系统和方法
CA3028122A1 (en) 2016-06-16 2017-12-21 Oncoselect Therapeutics, Llc Porphyrin compounds and compositions useful for treating cancer
CN107589189B (zh) * 2017-09-06 2018-07-10 中国农业科学院饲料研究所 一种氟甲喹的手性对映体的检测方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4930516B1 (en) * 1985-11-13 1998-08-04 Laser Diagnostic Instr Inc Method for detecting cancerous tissue using visible native luminescence
US4783529A (en) * 1985-12-03 1988-11-08 Research Corporation Technologies Rapid synthesis of radiolabeled porphyrin complexes for medical application
US4857300A (en) * 1987-07-27 1989-08-15 Cytocorp, Inc. Cytological and histological fixative formulation and methods for using same

Also Published As

Publication number Publication date
EP0533845A1 (de) 1993-03-31
HUT63499A (en) 1993-08-30
JPH06500164A (ja) 1994-01-06
FI925673A0 (fi) 1992-12-14
US5391547A (en) 1995-02-21
EP0533845B1 (de) 2003-10-08
WO1991019978A1 (en) 1991-12-26
NO924820L (no) 1993-02-12
AU8061491A (en) 1992-01-07
JP3047468B2 (ja) 2000-05-29
EP0533845A4 (en) 1993-11-18
WO1991019977A1 (en) 1991-12-26
AU8190691A (en) 1992-01-07
CA2085464C (en) 2002-12-17
NO924820D0 (no) 1992-12-14
US5162231A (en) 1992-11-10
AU670743B2 (en) 1996-08-01
DE69133325D1 (de) 2003-11-13
KR0171393B1 (ko) 1999-05-15
HU9203923D0 (en) 1993-03-29
FI925673A (fi) 1992-12-14
DK0533845T3 (da) 2004-02-16
BR9106563A (pt) 1993-06-22
RU2114430C1 (ru) 1998-06-27
DE69133325T2 (de) 2004-07-29
CA2085464A1 (en) 1991-12-16

Similar Documents

Publication Publication Date Title
ATE251750T1 (de) Verwendung von 5,10,15,20-tetrakis(r- carboxyphenyl)porphin zum nachweis und zur behandlung von lungenkrebs
RU92016479A (ru) Применение 5,10,15,20-тетракис (4-карбоксифенил) порфина для обнаружения и лечения рака легких
Spiess et al. Bone cancers induced by 224Ra (Th X) in children and adults
DeRiemer et al. BLEDTA: tumor localization by a bleomycin analog containing a metal-chelating group
Hambright et al. The distribution of various water soluble radioactive metalloporphyrins in tumor bearing mice
NL7600104A (nl) Dragermateriaal voor plaatsbepaling met radio-ak- tieve isotopen in medisch onderzoek en werkwijze voor de bereiding daarvan.
Mäntylä et al. Regional blood flow in human tumours with special reference to the effect of radiotherapy
Nakajima et al. TUMOR IMAGING WITH [111niIn] MONO‐DTPA‐ETHYLENEGLYCOL‐Ga‐DEUTEROPORPHYRIN
Lawrence Artificial radio-activity and neutron rays in biology and medicine
Doi et al. Preparation of 109Pd-hematoporphyrin for selective lymphatic ablation using N-methylhematoporphyrin
de Lima Radioisotopes in medicine
KR890701134A (ko) 중성자 포착 종양요법을 위한 리포조옴으로 캡슐화된 화합물의 조성물 및 사용방법
Son Radiation carcinogenesis
Cole et al. Method of using 5, 10, 15, 20-tetrakis (carboxyphenyl) porphine for detecting cancers of the lung
Ortalli et al. Gamma-rays from Mössbauer sources: a low-dose approach to cancer therapy
Gottschalk Semiannual Report to THE ATOMIC ENERGY COMMISSION. MARCH 1968
Barth et al. Studies on the hematogenous dissemination of technetium-99m labeled malignant cells
Kment et al. Indium 111-A-bleomycin—A new tracer for imaging orofacial neoplasms
BROWNE PREPARATION AND INVESTIGATION OF A TC-99M-HEMATOPORPHYRIN DERIVATIVE AS A TUMOR SCINTIGRAPHIC AGENT.
MacDonald et al. Short term tissue distribution of several radionuclides useful in bone scanning.
DE3875290D1 (de) Verwendung eines vehikels mit hoher affinitaet zu tumoren.
Yang et al. “Clear Plate” Technique for Localization and Orientation in Rectilinear Scanning
Cole et al. A synthetic porphyrin with high affinity for lung cancer cells and inflamed lymphatic tissue
Mallard et al. Lyoluminescence Accident Dosimetry With Desiccated Human Tissue and Personal Effects of the Victim.
Yamamoto et al. Threshold dose-rate observed by administration of tritiated water in mice for radiation risk

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0533845

Country of ref document: EP

REN Ceased due to non-payment of the annual fee